NO20064362L - Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic diseases - Google Patents
Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic diseasesInfo
- Publication number
- NO20064362L NO20064362L NO20064362A NO20064362A NO20064362L NO 20064362 L NO20064362 L NO 20064362L NO 20064362 A NO20064362 A NO 20064362A NO 20064362 A NO20064362 A NO 20064362A NO 20064362 L NO20064362 L NO 20064362L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- treatment
- methods
- pharmaceutical compositions
- metabolic diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer forbindelser anvendelige for eksempel for å modulere insulinnivåer hos et subjekt og som har den generelle formelen: Q - L1 - P - L2 - M - X - L3- A hvori definisjonene av variablene Q, L1, P, L2 , M, X, L3 og A er tilveiebrakt heri. Oppfinnelsen tilveiebringer også sammensetninger og fremgangsmåter for anvendelse av forbindelsene, for eksempel for behandling av type II diabetes.The present invention provides compounds useful, for example, for modulating insulin levels of a subject and having the general formula: Q - L1 - P - L2 - M - X - L3-A wherein the definitions of variables Q, L1, P, L2, M, X, L3 and A are provided herein. The invention also provides compositions and methods for the use of the compounds, for example, for the treatment of type II diabetes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54874104P | 2004-02-27 | 2004-02-27 | |
US60157904P | 2004-08-12 | 2004-08-12 | |
PCT/US2005/005815 WO2005086661A2 (en) | 2004-02-27 | 2005-02-24 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064362L true NO20064362L (en) | 2006-11-22 |
Family
ID=34976072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064362A NO20064362L (en) | 2004-02-27 | 2006-09-26 | Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic diseases |
Country Status (19)
Country | Link |
---|---|
US (2) | US7816367B2 (en) |
EP (1) | EP1737809B1 (en) |
JP (1) | JP5299810B2 (en) |
KR (1) | KR20070004769A (en) |
CN (1) | CN1946666A (en) |
AR (1) | AR048306A1 (en) |
AU (1) | AU2005220728B2 (en) |
BR (1) | BRPI0508098A (en) |
CA (1) | CA2558585C (en) |
CR (1) | CR8642A (en) |
EA (1) | EA011010B1 (en) |
EC (1) | ECSP066887A (en) |
ES (1) | ES2433466T3 (en) |
IL (1) | IL177717A0 (en) |
IS (1) | IS8542A (en) |
MA (1) | MA28466B1 (en) |
NO (1) | NO20064362L (en) |
TW (1) | TW200539854A (en) |
WO (1) | WO2005086661A2 (en) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
EP2253315A1 (en) * | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
NZ556546A (en) * | 2005-01-07 | 2011-02-25 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US8097610B2 (en) | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
DE602006016313D1 (en) | 2005-09-16 | 2010-09-30 | Arrow Therapeutics Ltd | BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C |
KR100968705B1 (en) * | 2005-10-27 | 2010-07-06 | 주식회사유한양행 | 2-phenylpyrimidine derivatives and processes for the preparation thereof |
UA95613C2 (en) | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Compounds for the treatment of metabolic disorders |
WO2007092729A2 (en) * | 2006-02-02 | 2007-08-16 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
EP2001844A2 (en) * | 2006-03-14 | 2008-12-17 | Amgen, Inc | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
AU2007292816B2 (en) * | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
US7750048B2 (en) * | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
TW200838526A (en) | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
US8394841B2 (en) | 2007-02-22 | 2013-03-12 | Irm Llc | Compounds and methods for modulating G protein-coupled receptors |
CA2683751C (en) * | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
BRPI0818253A2 (en) | 2007-10-10 | 2015-04-07 | Amgen Inc | Substituted biphenyl gpr40 modulators |
EP2684861A3 (en) * | 2007-10-26 | 2014-05-07 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
WO2009055932A1 (en) * | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
EP2674417A3 (en) * | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
EP2260017A1 (en) * | 2008-03-06 | 2010-12-15 | Amgen, Inc | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
EP2272817A4 (en) * | 2008-04-11 | 2011-12-14 | Inst Med Molecular Design Inc | Pai-1 inhibitor |
NZ588983A (en) * | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
JP2012503595A (en) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | Compounds for the treatment of metabolic diseases |
JP5551707B2 (en) * | 2008-10-15 | 2014-07-16 | アムジエン・インコーポレーテツド | Spirocyclic GPR40 regulator |
MX2011004125A (en) * | 2008-10-21 | 2011-05-19 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof. |
AR074760A1 (en) | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
JP2012136438A (en) * | 2009-04-22 | 2012-07-19 | Astellas Pharma Inc | Tetrazole compound |
AR078522A1 (en) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | SPIROPIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES AND INTERMEDIARY COMPOUND FOR SYNTHESIS |
DE102009046115A1 (en) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituted 3-phenylpropanoic acids and their use |
WO2011052756A1 (en) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisoxazole derivative |
AR078948A1 (en) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES |
EP2332427A1 (en) | 2009-12-07 | 2011-06-15 | Nestec S.A. | low caloric fat replacers |
EA201290574A1 (en) | 2009-12-25 | 2012-12-28 | Мотида Фармасьютикал Ко., Лтд. | NEW DERIVATIVE 3-HYDROXY-5-Arylisothiazole |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
WO2012076466A2 (en) | 2010-12-07 | 2012-06-14 | Bayer Pharma Aktiengesellschaft | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
US9499467B2 (en) | 2011-04-08 | 2016-11-22 | Caldan Therapeutics Limited | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
NZ617409A (en) | 2011-04-27 | 2015-08-28 | Mochida Pharm Co Ltd | Novel 3-hydroxyisothiazole 1-oxide derivative |
CA2834465A1 (en) | 2011-04-28 | 2012-11-01 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
AR087451A1 (en) | 2011-08-17 | 2014-03-26 | Lilly Co Eli | DERIVED FROM 1,2,3,4-TETRAHYDROQUINOLINE USEFUL FOR TREATMENT OF DIABETES |
WO2013057743A1 (en) * | 2011-10-21 | 2013-04-25 | Connexios Life Sciences Pvt. Ltd | Process for the preparation of an aryl oxime and salts thereof |
EP2800736A1 (en) * | 2012-01-04 | 2014-11-12 | Sanofi | 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament |
IN2014MN01839A (en) | 2012-02-28 | 2015-07-03 | Piramal Entpr Ltd | |
DE102012208530A1 (en) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituted piperidinoacetamides and their use |
RU2015106909A (en) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC TRICYCLIC COMPOUNDS |
TWI692469B (en) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient |
SI2920165T1 (en) | 2012-11-16 | 2017-02-28 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
EP2925751A1 (en) | 2012-12-03 | 2015-10-07 | F. Hoffmann-La Roche AG | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
DE102013201104A1 (en) * | 2013-01-24 | 2014-07-24 | H.C. Starck Gmbh | Process for the production of chromium nitride-containing spray powders |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
ES2709195T3 (en) * | 2013-02-28 | 2019-04-15 | Tiumbio Co Ltd | Tricyclic compound and use thereof |
CN104109115B (en) * | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | Phenylpropionic acid compound, its pharmaceutical composition, preparation method and the purposes of a kind of nitrogen heterocyclic ring link |
AR096041A1 (en) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | CARBOXYLIC ACID DERIVATIVES RENT REPLACED AS RPG AGONISTS |
KR101569522B1 (en) | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, preparation method thereof, and pharmaceutical composition for use in preventing or treating metabolic diseases containing the same as an active ingredient |
WO2015000412A1 (en) * | 2013-07-02 | 2015-01-08 | 四川海思科制药有限公司 | Benzocyclobutene derivative and preparation method and pharmaceutical application thereof |
CN104418801B (en) * | 2013-08-19 | 2016-10-05 | 上海润诺生物科技有限公司 | Benzo piperidine ring and benzo morpholine cyclics, its preparation method and medical applications |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP6352415B2 (en) | 2013-11-14 | 2018-07-04 | カディラ・ヘルスケア・リミテッド | Novel heterocyclic compounds |
EP3068768B1 (en) | 2013-11-15 | 2019-07-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
TW201609722A (en) | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | A novel triazolo-pyridine compound |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
KR20160095117A (en) | 2014-01-10 | 2016-08-10 | 일라이 릴리 앤드 캄파니 | Phenyl-triazolo-pyridine compounds |
CN105899509B (en) * | 2014-01-10 | 2018-01-02 | 伊莱利利公司 | Isopropyl triazolopyridine compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
DK3107901T3 (en) | 2014-02-19 | 2020-06-22 | Piramal Entpr Ltd | RELATIONSHIPS FOR USE AS GPR120 AGONISTS |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10273230B2 (en) | 2014-07-25 | 2019-04-30 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof |
WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016038540A1 (en) | 2014-09-11 | 2016-03-17 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
TW201629033A (en) | 2014-10-08 | 2016-08-16 | 健生藥品公司 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
ES2869910T3 (en) * | 2014-10-17 | 2021-10-26 | Hyundai Pharm Co Ltd | Compound preparation, containing a new 3- (4- (benzyloxy) phenyl) hex-4-ynoic acid derivative and another active ingredient, to prevent or treat metabolic diseases |
EP3233802A1 (en) | 2014-12-18 | 2017-10-25 | Bayer Pharma Aktiengesellschaft | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof |
US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
US9908873B2 (en) | 2015-08-12 | 2018-03-06 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
US9856245B2 (en) | 2015-08-12 | 2018-01-02 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
CN105198826A (en) * | 2015-10-08 | 2015-12-30 | 中国药科大学 | 3,5-dimethyl isoxazole derivatives, preparation method of derivatives, and application of derivatives as drugs |
EP3436003B1 (en) | 2016-03-29 | 2023-08-23 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
WO2017180457A1 (en) | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Gpr40 agonists in anti-diabetic drug combinations |
WO2017180571A1 (en) * | 2016-04-11 | 2017-10-19 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes |
CU24576B1 (en) | 2016-05-04 | 2022-02-04 | Centro De Investig Y Desarrollo De Medicamentos Cidem | PHENOLIC COMPOUND AND COMBINATION THEREOF WITH A BENZODIAZEPINE FUSED TO 1,4-DIHYDROPYRIDINE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL AND VASCULAR NERVOUS SYSTEM |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
KR102007633B1 (en) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | Novel phenyl propionic acid derivatives and uses thereof |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN109666027A (en) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | GPR40 agonist compound of a kind of amide structure and application thereof |
WO2019099315A1 (en) | 2017-11-16 | 2019-05-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
BR112020013694A2 (en) * | 2018-01-08 | 2020-12-01 | Celon Pharma S.A. | 3-phenyl-4-hexinoic acid derivatives as gpr40 agonists |
CN110092774B (en) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | Aromatic propionic acid derivative, preparation method and application thereof |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN113474335A (en) | 2019-02-21 | 2021-10-01 | 南京瑞捷医药科技有限公司 | Novel compounds and their use as thyroid hormone receptor agonists |
TW202140440A (en) * | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40 agonists |
WO2022269439A1 (en) * | 2021-06-21 | 2022-12-29 | Ildong Pharmaceutical Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
WO2023080299A1 (en) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | Novel salt of phenyl propionic acid derivative, method for producing same, and pharmaceutical composition containing same |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE305216B (en) | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
FR2359135A1 (en) | 1976-07-22 | 1978-02-17 | Hexachimie | Heterocyclyl substd. phenoxy-propanolamine - with cardio:selective beta-adrenergic blocking activity |
US4760089A (en) | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
DK303887A (en) | 1986-06-19 | 1987-12-20 | Smithkline Beckman Corp | DOPAMINE-BETA-HYDROXYLASE INHIBITORS AND PROCEDURES FOR PREPARING THEREOF |
GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
WO1993023041A1 (en) | 1992-05-20 | 1993-11-25 | Merck & Co., Inc. | Ester derivatives of 4-aza-steroids |
WO1993023040A1 (en) | 1992-05-20 | 1993-11-25 | Merck & Co., Inc. | 17-ethers and thioethers of 4-aza-steroids |
DE4241632A1 (en) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | New (aza)aromatic or alicyclic carboxylic acid cpds. - used e.g. for treating thrombosis, inflammation, osteoporosis, cardiac infarct or tumour metastasis |
US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
EP0706508A1 (en) | 1993-06-30 | 1996-04-17 | The Wellcome Foundation Limited | Anti-atherosclerotic diaryl compounds |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
CA2207618A1 (en) * | 1994-12-23 | 1996-07-04 | Helmut Pieper | Piperazine derivatives, medicaments comprising these compounds, their use and processes for their preparation |
AU6490396A (en) | 1995-07-14 | 1997-02-18 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
AU725998B2 (en) | 1995-09-18 | 2000-10-26 | Eisai R&D Management Co., Ltd. | Treating NIDDM with RXR agonists |
US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
EP1336600A3 (en) | 1995-10-06 | 2004-07-07 | Ligand Pharmaceuticals Incorporated | Dimer-selective RXR modulators and methods for their use |
US5771109A (en) * | 1996-05-17 | 1998-06-23 | Pixar | Method and apparatus for digitizing films using a stroboscopic scanning system |
JPH10316641A (en) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | Carboxylic acid derivative |
WO1999011255A1 (en) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
ATE451346T1 (en) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | CARBOXYLIC ACID DERIVATIVES AND MEDICATIONS THAT CONTAIN THEM AS THE ACTIVE INGREDIENTS |
MA26634A1 (en) | 1998-06-04 | 2004-12-20 | Astra Ab | NOVEL 3-ARYL PROPIONIC ACID DERIVATIVES AND THE LIKE |
DE19941567A1 (en) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | New liquid crystal compounds containing 3-hydroxyacrylic acid ester units, having high clear point, dielectric anisotropy and double refraction, useful e.g. in displays or (electro)optical components |
CA2362862A1 (en) * | 1999-02-16 | 2000-08-24 | Aventis Pharma Limited | Bicyclic compounds and their use as integrin receptor ligands |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
KR100693771B1 (en) | 1999-04-28 | 2007-03-12 | 사노피-아벤티스 도이칠란트 게엠베하 | Tri-aryl acid derivatives as PPAR receptor ligands and pharmaceutical compositions containing the same |
ATE263162T1 (en) | 1999-05-05 | 2004-04-15 | Aventis Pharma Ltd | UREA DERIVATIVES AND THEIR USE AS CELL ADHESION MODULATORS |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
JP2001242165A (en) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | Reagent for collecting blood |
JP2002003368A (en) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | Pharmaceutical preparation for percutaneous absorption or absorption through mucous membrane |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
DE60139025D1 (en) | 2000-12-28 | 2009-07-30 | Takeda Pharmaceutical | ALKANIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
KR20040030658A (en) * | 2001-06-07 | 2004-04-09 | 일라이 릴리 앤드 캄파니 | Modulators of peroxisome proliferator activated receptors(ppar) |
CN1293042C (en) | 2002-02-07 | 2007-01-03 | 远藤仁 | Aromatic amino acid derivates and medicinal compositions |
WO2003068959A1 (en) | 2002-02-14 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Novel screening method |
US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
JP4638735B2 (en) | 2002-06-24 | 2011-02-23 | タフツ ユニバーシティー | Silk biomaterial and method of using the same |
US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
JP4594611B2 (en) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | Receptor function regulator |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | Condensed ring compound |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
EP1697333A4 (en) | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
WO2005087710A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
EP2253315A1 (en) * | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
JP2007269630A (en) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | Insulin secretion promoter |
US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
JP2007284350A (en) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | Therapeutic agent for diabetes |
AU2006211514A1 (en) | 2005-01-28 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
AU2006210954A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
-
2005
- 2005-02-24 EP EP05723623.4A patent/EP1737809B1/en active Active
- 2005-02-24 CA CA2558585A patent/CA2558585C/en not_active Expired - Fee Related
- 2005-02-24 CN CNA2005800127092A patent/CN1946666A/en active Pending
- 2005-02-24 EA EA200601388A patent/EA011010B1/en not_active IP Right Cessation
- 2005-02-24 US US10/591,214 patent/US7816367B2/en active Active
- 2005-02-24 BR BRPI0508098-3A patent/BRPI0508098A/en not_active IP Right Cessation
- 2005-02-24 AU AU2005220728A patent/AU2005220728B2/en not_active Ceased
- 2005-02-24 WO PCT/US2005/005815 patent/WO2005086661A2/en active Application Filing
- 2005-02-24 ES ES05723623T patent/ES2433466T3/en active Active
- 2005-02-24 JP JP2007500959A patent/JP5299810B2/en not_active Expired - Fee Related
- 2005-02-24 KR KR1020067019713A patent/KR20070004769A/en not_active Application Discontinuation
- 2005-02-25 US US11/067,377 patent/US7649110B2/en active Active
- 2005-02-28 AR ARP050100748A patent/AR048306A1/en unknown
- 2005-03-01 TW TW094106166A patent/TW200539854A/en unknown
-
2006
- 2006-08-27 IL IL177717A patent/IL177717A0/en unknown
- 2006-09-13 MA MA29319A patent/MA28466B1/en unknown
- 2006-09-20 CR CR8642A patent/CR8642A/en not_active Application Discontinuation
- 2006-09-26 NO NO20064362A patent/NO20064362L/en not_active Application Discontinuation
- 2006-09-27 IS IS8542A patent/IS8542A/en unknown
- 2006-09-27 EC EC2006006887A patent/ECSP066887A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US7816367B2 (en) | 2010-10-19 |
AU2005220728B2 (en) | 2009-08-06 |
IS8542A (en) | 2006-09-27 |
EA011010B1 (en) | 2008-12-30 |
EA200601388A1 (en) | 2007-02-27 |
CR8642A (en) | 2008-11-28 |
AU2005220728A2 (en) | 2005-09-22 |
US7649110B2 (en) | 2010-01-19 |
IL177717A0 (en) | 2006-12-31 |
JP2007525516A (en) | 2007-09-06 |
AR048306A1 (en) | 2006-04-19 |
AU2005220728A1 (en) | 2005-09-22 |
WO2005086661A3 (en) | 2006-05-04 |
US20060004012A1 (en) | 2006-01-05 |
US20070142384A1 (en) | 2007-06-21 |
TW200539854A (en) | 2005-12-16 |
ECSP066887A (en) | 2006-11-24 |
CN1946666A (en) | 2007-04-11 |
MA28466B1 (en) | 2007-03-01 |
BRPI0508098A (en) | 2007-07-17 |
EP1737809A2 (en) | 2007-01-03 |
CA2558585A1 (en) | 2005-09-22 |
ES2433466T3 (en) | 2013-12-11 |
CA2558585C (en) | 2010-10-12 |
JP5299810B2 (en) | 2013-09-25 |
EP1737809B1 (en) | 2013-09-18 |
WO2005086661A2 (en) | 2005-09-22 |
KR20070004769A (en) | 2007-01-09 |
EP1737809A4 (en) | 2007-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064362L (en) | Compounds, pharmaceutical compositions and methods for use in the treatment of metabolic diseases | |
NO20072199L (en) | Thrombopoietin activity modulating compounds and methods | |
WO2007062078A3 (en) | Thrombopoietin activity modulating compounds and methods | |
NO20065847L (en) | Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase | |
EA200601837A1 (en) | PETROXASES FOR TREATMENT OF RESPIRATORY DISEASES | |
DK2212283T3 (en) | Substituted N-phenylbipyrrolidine carboxamides and therapeutic use thereof | |
NO20064325L (en) | Heteroberlaminopyrazole derivatives useful for the treatment of diabetes | |
NO20090321L (en) | Use of substituted 2-aminotyethralines for the manufacture of a drug for the prevention, relief and / or treatment of various types of pain | |
NO20064078L (en) | Substituted azetidine compositions, their preparation and use as drugs | |
DK2212282T3 (en) | Substituted N-phenylbipyrrolidine carboxamides and therapeutic use thereof | |
NO20075706L (en) | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods | |
CY1115690T1 (en) | ARTHROSPIRA BASED COMPOSITIONS AND THEIR USES | |
NO20063103L (en) | N-aryl-piperidine-substituted biphenyl carboxamides | |
MA31889B1 (en) | SUBSTITUTED N-PHENYL-BIPYRROLIDINE-UREES AND THERAPEUTIC USE THEREOF | |
NO20076357L (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
NO20073830L (en) | Medications for the treatment or prevention of fibrotic diseases | |
DE602005010744D1 (en) | PIPERAZINYLPYRIDINE DERIVATIVES AS AGENTS AGAINST ADIPOSITAS | |
NO20063859L (en) | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and use thereof as medicaments | |
ATE531703T1 (en) | BENZOCHROMEDER DERIVATIVES | |
DE602004013202D1 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES BY USING SCD4 INHIBITORS | |
EA200701813A1 (en) | NEW AMIDO-SUBSTITUTED 6-PHENYLPHENANTHRIDINES | |
NO20063790L (en) | Substituted azetidine compositions as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments | |
CY1110156T1 (en) | Substituted Compounds 4,5,6,7-tetrahydro-benzothiiazol-2-ylamine | |
NO20063860L (en) | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as pharmaceuticals | |
TNSN06263A1 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |